Browsing Tag
German Cancer Aid
1 post
Syntara’s (ASX: SNT) AZALOX trial clears first safety hurdle and advances to final 200 mg cohort
Syntara Limited has advanced its AZALOX study into the final Phase 1b cohort after the first patients completed treatment without dose-limiting toxicities, keeping a preliminary Q4 2026 data release on track.